Skip to main navigation menu Skip to main content Skip to site footer

Admin menu

Volume 8 (2021): Issue 1

Web-based Application for the Population Pharmacokinetic Service (WAPPS)'s impact on dosage selection: a single paediatric centre experience

Abstract

Abstract Background

Current treatment for severe haemophilia includes prophylactic factor replacement to prevent bleeding. Coagulation factor products have significant inter-patient variability in pharmacokinetic (PK) parameters. Optimal management requires tailoring prophylaxis to individual PK parameters. Web-based Application for the Population Pharmacokinetic Service (WAPPS) is a tool that estimates individual PK values using a population approach. Despite its growing use to help guide dosing selection, few studies have investigated its clinical impact.

Aim

To investigate any change in prophylaxis regimen and hours per week where factor level is under 1%, pre- and post-PK testing using WAPPS, for paediatric patients with severe haemophilia.

Methods

A retrospective chart review was conducted for all paediatric patients with severe haemophilia receiving care between April 2013 and July 2018 at McMaster Children's Hospital who have used WAPPS. Data extracted included: patient demographics, PK data generated by WAPPS, prophylaxis regimen pre- and post-PK testing, and reason for regimen change. The number of hours per week where factor level was under 1% pre- and post-PK testing was calculated using WAPPS.

Results

Thirty-one patients were included; 42% (n=13) changed their prophylaxis regimen after PK testing. After using PK data to personalise prophylaxis recommendations, there was a decrease in the number of hours per week where factor level is under 1% (from an average of 13.1 hours/week to 11.8 hours/week), though not statistically significant (p=0.16).

Conclusion

PK data generated by WAPPS has direct impact by informing changes to prophylaxis recommendations. This individualised approach promotes patient-centred care and patient engagement without increasing the time spent with factor levels below 1%. It also confirms and validates clinical practice.

Article

View Full Article

References

  • 1. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev 2011; (9): CD003429. doi: https://doi.org/10.1002/14651858.CD003429.pub4.
  • 2. Valentino LA, Mamonov V, Hellmann A, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost 2012; 10(3): 359–67. doi: https://doi.org/10.1111/j.1538-7836.2011.04611.x.
  • 3. Collins PW, Bjorkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8(2): 269–75. doi: https://doi.org/10.1111/j.1538-7836.2009.03703.x.
  • 4. Björkman S, Folkesson A, Jönsson S. Pharmacokinetics and dose requirements of factor VIII over the age range 3–74 years. Eur J Clin Pharmacol 2009; 65(10): 989–98. doi: https://doi.org/10.1007/s00228-009-0676-x.
  • 5. Iorio A, Keepanasseril A, Foster G, et al. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc 2016; 5(4): e239. doi: https://doi.org/10.2196/resprot.6558.
  • 6. Feldman BM, Pai M, Rivard GE, et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4(6): 1228–36. doi: https://doi.org/10.1111/j.1538-7836.2006.01953.x.
  • 7. Nagao A, Yeung CHT, Germini F, Suzuki T. Clinical outcomes in hemophilia A patients undergoing tailoring of prophylaxis based on population-based pharmacokinetic dosing. Thromb Res 2019; 173: 79–84. doi: https://doi.org/10.1016/j.thromres.2018.11.017.
  • 8. Croteau SE, Wheeler AP, Khan O, et al. Pharmacokinetic-tailored approach to hemophilia prophylaxis: Medical decision making and outcomes. Res Pract Thromb Haemost 2020; 4(2): 326–33. doi: https://doi.org/10.1002/rth2.12305.
  • 9. Stemberger M, Kallenbach F, Schmit E, et al. Impact of adopting population pharmacokinetics for tailoring prophylaxis in haemophilia A patients: a historically controlled observational study. Thromb Haemost 2019; 119(3): 368–76. doi: https://doi.org/10.1055/s-0039-1677700.
  • 10. Pasca S, Milan M, Sarolo L, Zanon E. PK-driven prophylaxis versus standard prophylaxis: When a tailored treatment may be a real and achievable cost-saving approach in children with severe hemophilia A. Thromb Res 2017; 157: 58–63. doi: https://doi.org/10.1016/j.thromres.2017.07.003.
  • 11. Lim SY, Pettit RS. Pharmacokinetic considerations in pediatric pharmacotherapy. Am J Health Syst Pharm 2019; 76(19): 1472–80. doi: https://doi.org/10.1093/ajhp/zxz161.

PDF Download

Download PDF

Open in full-page viewer

Authors

  • Celia Kwan

    ORCID iD
    Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
  • Mihir D. Bhatt

    ORCID iD
    Department of Paediatrics, McMaster University, Hamilton, ON, Canada ; Hamilton Niagara Regional Hemophilia Program, McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada
  • Karen Strike

    ORCID iD
    Hamilton Niagara Regional Hemophilia Program, McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada ; School of Rehabilitation Science, Faculty of Health Science, McMaster University, Hamilton, ON, Canada
  • Kay Decker

    ORCID iD
    Hamilton Niagara Regional Hemophilia Program, McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada
  • Davide Matino

    ORCID iD
    Hamilton Niagara Regional Hemophilia Program, McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada ; Department of Medicine, McMaster University, Hamilton, ON, Canada
  • Anthony K.C. Chan

    ORCID iD
    akchan@mcmaster.ca
    Department of Paediatrics, McMaster University, Hamilton, ON, Canada ; Hamilton Niagara Regional Hemophilia Program, McMaster Children's Hospital, Hamilton Health Sciences, Hamilton, ON, Canada .